HIGHLIGHTS
- who: Xiaocong Pang from the (UNIVERSITY) have published the article: Discovery of C19-9 as a novel non-RGD inhibitor of u03b1vu03b23 to overcome enzalutamide resistance in castration-resistant prostate cancer, in the Journal: (JOURNAL) of 29/06/2022
SUMMARY
Received 3 mg/kg per day, C19-9 significantly inhibited the increase of tumor volume in 22RV1 xenografts (Fig 1j, Supplementary Fig S8a). In contrast, the CRPC 22RV1 xenografts were resistant to enzalutamide administration. C19-9 did not significantly affect the body weight of mice in acute and longterm toxicity experiments, and did . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.